Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand
This study evaluated lifetime liver-related clinical outcomes, costs of treatment, and the cost-effectiveness of treatment options for non-alcoholic fatty liver disease (NAFLD) in Thailand.
A cost-utility analysis using a lifetime Markov model was conducted among Thai patients with NAFLD, from a societal perspective. Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs). One-way and probabilistic sensitivity analyses were performed.
When compared with usual care, a weight reduction program can prevent cirrhosis and HCC cases by 13.91% (95% credible interval [CrI] 0.97, 20.59) and 2.12% (95% CrI 0.43, 4.56), respectively; pioglitazone can prevent cirrhosis and HCC cases by 9.30% (95% CrI −2.52, 15.24) and 1.42% (95% CrI −0.18, 3.74), respectively; and vitamin E can prevent cirrhosis and HCC cases by 7.32% (95% CrI −4.64, 15.56) and 1.12% (95% CrI −0.81, 3.44), respectively. Estimated incremental life expectancy and incremental QALYs for all treatment options compared with usual care were approximately 0.06 years and 0.07 QALYs, respectively. The lifetime costs of both a weight reduction program and pioglitazone were less than usual care, while vitamin E was $3050 (95% CrI 2354, 3650). The weight reduction program dominated all other treatment options. The probability of being cost-effective in Thailand’s willingness-to-pay threshold ($4546/QALY gained) was 76% for the weight reduction program, 22% for pioglitazone, 2% for usual care, and 0% for vitamin E.
A weight reduction program can prevent cirrhosis and HCC occurrences, and dominates all other treatment options. Pioglitazone and vitamin E demonstrated a trend towards decreasing the number of cirrhosis and HCC cases.
The authors wish to thank Peter Barton from the writing clinic at Naresuan University Language Center for editing this work.
BC and PP participated in the study concept and design, data acquisition, data analysis, data interpretation, manuscript drafting, and critical revision and final review of the manuscript. RS, PD and NC participated in the study concept and design, data interpretation, manuscript drafting, and critical revision and final review of the manuscript.
Compliance with ethical standards
Conflicts of interest
Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Sawangjit, Piyameth Dilokthornsakul, and Nathorn Chaiyakunapruk declare no potential conflicts of interest with respect to the research, organization, and publication of this work.
The authors received no specific funding for this work.
- 1.Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Hepatology. 2012;55:2005–23.CrossRefGoogle Scholar
- 4.Sayiner M, Otgonsuren M, Cable R, Younossi I, Afendy M, Golabi P, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol. 2017;51:254–60.Google Scholar
- 7.Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study. F1000Research. 2017;6:1630.Google Scholar
- 8.Phisalprapa P, Ujjin A, Apisarnthanarak P, Charoensak A, Washirasaksiri C, Srivanichakorn W, et al. Sa1050 Prevalence and risk factors of non-alcoholic fatty liver disease in asian individuals with metabolic syndrome. Gastroenterology. 2014;146:S-947.Google Scholar
- 9.EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121–40.Google Scholar
- 11.Sub-Committee of Thai Working Group on Health Technology Assessment. Thailand’s National Health Technology Assessment Guidelines. Nonthaburi: The Graphico Systems Co., Ltd.; 2009.Google Scholar
- 18.Pachanee K, Wongphan T, Prakongsai P. Economic evaluation and budget impact analysis of liver transplantation among thai adults in universal health insurance coverage in Thailand. J Health Sci. 2016;25:908–19.Google Scholar
- 19.Subwongcharoen S, Treepongkaruna SA, Leelawat K, Ruksakul K. Long-term outcome of patients undergoing liver transplantation at Rajavithi Hospital, Thailand. J Med Assoc Thai. 2012;95:1292–6.Google Scholar
- 21.Bureau of Non-communicable Diseases. Mortality rates of patients with non-communicable diseases in Thailand. Annaul report. 2015. http://thaincd.com/document/file/download/paper-manual/Annual-report-2015.pdf. Accessed 20 Dec 2017.
- 22.World Health Organization. Life tables: Thailand. 2013. http://apps.who.int/gho/data/node.country.country-THA?lang=en. Accessed 16 Nov 2016.
- 24.Leerapun A, Thaikruea L, Pisespongsa P, Chitapanarux T, Praisontarangkul OA, Thongsawat S. Clinical features and prognostic factors for liver cancer from a referral center in northern Thailand. J Med Assoc Thai. 2013;96:531–7.Google Scholar
- 33.Riewpaiboon A. Standard cost list for health technology assessment. 2009. http://www.hitap.net/costingmenu/. Accessed 12 Dec 2016.
- 34.Drug and Medical Supply Information Center. Drug information service: Thailand. 2016. http://dmsic.moph.go.th/dmsic/index.php?&p=1&type=3&t=3&id=1. Accessed 16 Jul 2016.
- 36.Sub-committee of Thai Working Group on Health Technology Assessment. In: Meeting report of 2nd annual meeting. 2013.Google Scholar
- 46.Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8:3924–34.Google Scholar